이소옥사졸린 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)

The global demand for Isoxazoline Market is presumed to reach the market size of nearly USD 5.45 Billion by 2032 from USD 1.6 Billion in 2023 with a CAGR of 14.55% under the study period 2024-2032.

Isoxazoline is a class of five-membered heterocyclic compounds, comprising one atom each of oxygen and nitrogen, located adjacent to each other. It can be produced by the 1,3-dipolar cycloaddition of nitrile oxides with alkenes, 2-isoxazolines by N-methylation, and cycloaddition between a nitrone and an alkyne. Isoxazolines have a variety of uses, with many being biologically active. They exhibit a broad spectrum of insecticidal and acaricidal activity and are effective against many veterinary parasites such as fleas and ticks.

MARKET DYNAMICS

The global isoxazoline market is estimated to grow at a steady rate during the forecast period. Increasing parasite attacks on pets, advancing research on the potentials of isoxazoline, and rising pet ownership are factors steering the global isoxazoline market. Isoxazoline is finding its expanding use and exploration in pharmaceuticals and therapeutics due to the properties such as insecticidal, antibacterial, antibiotic, antitumor, antifungal, antituberculosis, anticancer, and ulcerogenic. In addition, Isoxazoline has gained much significance in the field of medicinal chemistry as an anticancer agent. However, few alerts were received from the FDA about isoxazoline's potential for neurologic adverse events in dogs and cats, restraining market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Isoxazoline. The growth and trends of Isoxazoline industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Isoxazoline market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

• Fluralaner
• Afoxolaner
• Sarolaner
• Lotilaner

By Pet Type

• Cat
• Dog

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Isoxazoline market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Isoxazoline market include Merck Animal Health Inc, Elanco Animal Health Incorporated, Boehringer Ingelheim International GmbH, Zoetis Inc. Etc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ISOXAZOLINE - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product Type
  • 3.7.2 Market Attractiveness Analysis By Pet Type
  • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ISOXAZOLINE MARKET ANALYSIS BY PRODUCT TYPE

• 5.1. Overview By Product Type
• 5.2. Historical and Forecast Data Analysis By Product Type
• 5.3. Fluralaner Historic and Forecast Sales By Regions
• 5.4. Afoxolaner Historic and Forecast Sales By Regions
• 5.5. Sarolaner Historic and Forecast Sales By Regions
• 5.6. Lotilaner Historic and Forecast Sales By Regions

6. GLOBAL ISOXAZOLINE MARKET ANALYSIS BY PET TYPE

• 6.1. Overview By Pet Type
• 6.2. Historical and Forecast Data Analysis By Pet Type
• 6.3. Cat Historic and Forecast Sales By Regions
• 6.4. Dog Historic and Forecast Sales By Regions

7. GLOBAL ISOXAZOLINE MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2 North America By Segment Sales Analysis
  • 7.3.3 North America By Country Sales Analysis
  • 7.3.4 United States Sales Analysis
  • 7.3.5 Canada Sales Analysis
  • 7.3.6 Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2 Europe By Segment Sales Analysis
  • 7.4.3 Europe By Country Sales Analysis
  • 7.4.4 United Kingdom Sales Analysis
  • 7.4.5 France Sales Analysis
  • 7.4.6 Germany Sales Analysis
  • 7.4.7 Italy Sales Analysis
  • 7.4.8 Russia Sales Analysis
  • 7.4.9 Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2 Asia Pacific By Segment Sales Analysis
  • 7.5.3 Asia Pacific By Country Sales Analysis
  • 7.5.4 China Sales Analysis
  • 7.5.5 India Sales Analysis
  • 7.5.6 Japan Sales Analysis
  • 7.5.7 South Korea Sales Analysis
  • 7.5.8 Australia Sales Analysis
  • 7.5.9 South East Asia Sales Analysis
  • 7.5.10 Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2 Latin America By Segment Sales Analysis
  • 7.6.3 Latin America By Country Sales Analysis
  • 7.6.4 Brazil Sales Analysis
  • 7.6.5 Argentina Sales Analysis
  • 7.6.6 Peru Sales Analysis
  • 7.6.7 Chile Sales Analysis
  • 7.6.8 Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2 Middle East & Africa By Segment Sales Analysis
  • 7.7.3 Middle East & Africa By Country Sales Analysis
  • 7.7.4 Saudi Arabia Sales Analysis
  • 7.7.5 UAE Sales Analysis
  • 7.7.6 Israel Sales Analysis
  • 7.7.7 South Africa Sales Analysis
  • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE ISOXAZOLINE COMPANIES

• 8.1. Isoxazoline Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9. COMPANY PROFILES OF ISOXAZOLINE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Merck Animal Health Inc
  • 9.3.1 Company Overview
  • 9.3.2 Company Revenue
  • 9.3.3 Products
  • 9.3.4 Recent Developments
• 9.4. Elanco Animal Health Incorporated
  • 9.4.1 Company Overview
  • 9.4.2 Company Revenue
  • 9.4.3 Products
  • 9.4.4 Recent Developments
• 9.5. Boehringer Ingelheim International GmbH
  • 9.5.1 Company Overview
  • 9.5.2 Company Revenue
  • 9.5.3 Products
  • 9.5.4 Recent Developments
• 9.6. Zoetis Inc. Etc
  • 9.6.1 Company Overview
  • 9.6.2 Company Revenue
  • 9.6.3 Products
  • 9.6.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies